



f DIVA

A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease
Alpha Trial Link:
https://clinicaltrials.gov/ct2/show/NCT03653247?term=NCT03653247&rank=1
Alpha Clinic (primary): UCSF
Contact:
Name:
Julie DeCaris
Phone:
510-428-3885. ext.2739
Email:
jdecaris@mail.cho.org
Alpha Trial Sponsor:
Bioverativ Therapeutics, Inc
Disease Indication:
Sickle Cell Disease
Enrollment Status:
Recruiting

 $\textbf{Source URL:} \ https://www.cirm.ca.gov/alphaclinictrial/phase-12-open-label-multicenter-single-arm-study-assess-safety-tolerability-and alphaclinictrial/phase-12-open-label-multicenter-single-arm-study-assess-safety-tolerability-and alphaclinictrial/phase-safety-arm-study-assess-safety-arm-study-arm-study-arm-study-arm-study-arm-study-arm-study-arm-study-arm-study-arm-study-arm-study-arm-study-a$